Enanta Pharmaceuticals (ENTA) Change in Acquisitions & Divestments (2012 - 2026)

Enanta Pharmaceuticals has reported Change in Acquisitions & Divestments for 15 years, with the latest figure at $53.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 1.36% year-over-year to $53.9 million; the trailing twelve-month figure through Mar 2026 stood at $287.4 million (up 13.07% YoY), and the FY2025 full-year result was $262.9 million, down 31.45% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $53.9 million, down from $101.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $134.5 million in Q4 2023, with the low at $26.7 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $73.5 million across 5 years, with a median of $72.4 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments soared 210.73% — and 2024, when it slumped 76.51%.
• Enanta Pharmaceuticals' Change in Acquisitions & Divestments stood at $104.1 million in 2022, then climbed by 29.22% to $134.5 million in 2023, then plunged by 42.28% to $77.6 million in 2024, then jumped by 30.68% to $101.5 million in 2025, then tumbled by 46.87% to $53.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $53.9 million (Q1 2026), $101.5 million (Q4 2025), and $72.4 million (Q3 2025), per Business Quant data.